Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q3 2025 value amounting to $2.3 million.

  • Rani Therapeutics Holdings' Share-based Compensation fell 4201.93% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year decrease of 1800.19%. This contributed to the annual value of $16.0 million for FY2024, which is 1566.18% down from last year.
  • According to the latest figures from Q3 2025, Rani Therapeutics Holdings' Share-based Compensation is $2.3 million, which was down 4201.93% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Rani Therapeutics Holdings' Share-based Compensation peaked at $18.7 million during Q3 2021, and registered a low of $282000.0 during Q2 2021.
  • Over the past 5 years, Rani Therapeutics Holdings' median Share-based Compensation value was $4.0 million (recorded in 2024), while the average stood at $4.4 million.
  • Data for Rani Therapeutics Holdings' Share-based Compensation shows a peak YoY increase of 130992.91% (in 2022) and a maximum YoY decrease of 7645.49% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Share-based Compensation stood at $3.2 million in 2021, then soared by 42.19% to $4.5 million in 2022, then dropped by 0.29% to $4.5 million in 2023, then dropped by 11.03% to $4.0 million in 2024, then plummeted by 41.29% to $2.3 million in 2025.
  • Its Share-based Compensation was $2.3 million in Q3 2025, compared to $3.3 million in Q2 2025 and $3.9 million in Q1 2025.